nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—liver cancer—hepatitis B	0.602	1	CtDrD
Sorafenib—ABCC4—Adefovir Dipivoxil—hepatitis B	0.0817	0.423	CbGbCtD
Sorafenib—ABCC4—Lamivudine—hepatitis B	0.0479	0.248	CbGbCtD
Sorafenib—ABCC2—Lamivudine—hepatitis B	0.0285	0.148	CbGbCtD
Sorafenib—ABCG2—Lamivudine—hepatitis B	0.0258	0.133	CbGbCtD
Sorafenib—Hepatic pain—Telbivudine—hepatitis B	0.0094	0.101	CcSEcCtD
Sorafenib—ABCB1—Lamivudine—hepatitis B	0.00929	0.0481	CbGbCtD
Sorafenib—Hepatocellular carcinoma—Entecavir—hepatitis B	0.00522	0.0563	CcSEcCtD
Sorafenib—Hepatic cancer—Entecavir—hepatitis B	0.00475	0.0513	CcSEcCtD
Sorafenib—Disease progression—Telbivudine—hepatitis B	0.00359	0.0387	CcSEcCtD
Sorafenib—ABCC2—bile duct—hepatitis B	0.00296	0.071	CbGeAlD
Sorafenib—Lipase increased—Telbivudine—hepatitis B	0.00267	0.0288	CcSEcCtD
Sorafenib—Abdominal pain lower—Telbivudine—hepatitis B	0.00246	0.0266	CcSEcCtD
Sorafenib—Ascites—Entecavir—hepatitis B	0.0021	0.0226	CcSEcCtD
Sorafenib—Amylase increased—Telbivudine—hepatitis B	0.00165	0.0178	CcSEcCtD
Sorafenib—FLT3—blood plasma—hepatitis B	0.00163	0.0389	CbGeAlD
Sorafenib—Hypophosphataemia—Adefovir Dipivoxil—hepatitis B	0.0016	0.0173	CcSEcCtD
Sorafenib—RALBP1—blood plasma—hepatitis B	0.00121	0.0289	CbGeAlD
Sorafenib—FLT1—blood plasma—hepatitis B	0.00115	0.0275	CbGeAlD
Sorafenib—STK10—blood plasma—hepatitis B	0.00109	0.026	CbGeAlD
Sorafenib—UGT1A1—blood plasma—hepatitis B	0.00103	0.0246	CbGeAlD
Sorafenib—Hoarseness—Lamivudine—hepatitis B	0.001	0.0108	CcSEcCtD
Sorafenib—KDR—blood plasma—hepatitis B	0.00097	0.0232	CbGeAlD
Sorafenib—Rhinorrhoea—Telbivudine—hepatitis B	0.000967	0.0104	CcSEcCtD
Sorafenib—CSF1R—blood plasma—hepatitis B	0.000947	0.0227	CbGeAlD
Sorafenib—Amylase increased—Lamivudine—hepatitis B	0.000927	0.01	CcSEcCtD
Sorafenib—Rhabdomyolysis—Telbivudine—hepatitis B	0.000886	0.00955	CcSEcCtD
Sorafenib—KIT—blood plasma—hepatitis B	0.00086	0.0206	CbGeAlD
Sorafenib—Suicide—Lamivudine—hepatitis B	0.000851	0.00918	CcSEcCtD
Sorafenib—TAOK2—blood—hepatitis B	0.000821	0.0197	CbGeAlD
Sorafenib—Hepatic function abnormal—Adefovir Dipivoxil—hepatitis B	0.000773	0.00834	CcSEcCtD
Sorafenib—Hepatic failure—Entecavir—hepatitis B	0.00077	0.00831	CcSEcCtD
Sorafenib—Influenza like illness—Telbivudine—hepatitis B	0.000761	0.00821	CcSEcCtD
Sorafenib—Hepatic failure—Adefovir Dipivoxil—hepatitis B	0.000752	0.00811	CcSEcCtD
Sorafenib—Completed suicide—Lamivudine—hepatitis B	0.000751	0.0081	CcSEcCtD
Sorafenib—ZAK—blood—hepatitis B	0.000715	0.0171	CbGeAlD
Sorafenib—Folliculitis—Lamivudine—hepatitis B	0.000703	0.00758	CcSEcCtD
Sorafenib—HIPK3—blood—hepatitis B	0.0007	0.0168	CbGeAlD
Sorafenib—ABCC4—blood plasma—hepatitis B	0.000669	0.016	CbGeAlD
Sorafenib—CDK7—liver—hepatitis B	0.000647	0.0155	CbGeAlD
Sorafenib—TAOK2—liver—hepatitis B	0.000642	0.0154	CbGeAlD
Sorafenib—Abdominal pain upper—Entecavir—hepatitis B	0.000632	0.00682	CcSEcCtD
Sorafenib—BRAF—blood—hepatitis B	0.000627	0.015	CbGeAlD
Sorafenib—Oropharyngeal discomfort—Lamivudine—hepatitis B	0.000607	0.00655	CcSEcCtD
Sorafenib—EPHX2—blood—hepatitis B	0.0006	0.0144	CbGeAlD
Sorafenib—Alanine aminotransferase increased—Adefovir Dipivoxil—hepatitis B	0.000596	0.00643	CcSEcCtD
Sorafenib—FLT3—blood—hepatitis B	0.000595	0.0143	CbGeAlD
Sorafenib—Pancreatitis—Entecavir—hepatitis B	0.000587	0.00633	CcSEcCtD
Sorafenib—Pancreatitis—Adefovir Dipivoxil—hepatitis B	0.000572	0.00617	CcSEcCtD
Sorafenib—Pain in extremity—Telbivudine—hepatitis B	0.000569	0.00614	CcSEcCtD
Sorafenib—Neutropenia—Entecavir—hepatitis B	0.00056	0.00604	CcSEcCtD
Sorafenib—ZAK—liver—hepatitis B	0.00056	0.0134	CbGeAlD
Sorafenib—CYP2C19—blood plasma—hepatitis B	0.000556	0.0133	CbGeAlD
Sorafenib—HIPK3—liver—hepatitis B	0.000548	0.0131	CbGeAlD
Sorafenib—Rhinorrhoea—Lamivudine—hepatitis B	0.000545	0.00588	CcSEcCtD
Sorafenib—FLT4—blood—hepatitis B	0.000541	0.013	CbGeAlD
Sorafenib—Dysphonia—Lamivudine—hepatitis B	0.000537	0.00579	CcSEcCtD
Sorafenib—Weight decreased—Adefovir Dipivoxil—hepatitis B	0.000528	0.0057	CcSEcCtD
Sorafenib—Renal failure—Entecavir—hepatitis B	0.000525	0.00566	CcSEcCtD
Sorafenib—Abdominal pain upper—Telbivudine—hepatitis B	0.00052	0.0056	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Telbivudine—hepatitis B	0.000512	0.00552	CcSEcCtD
Sorafenib—Renal failure—Adefovir Dipivoxil—hepatitis B	0.000512	0.00552	CcSEcCtD
Sorafenib—TIE1—liver—hepatitis B	0.000512	0.0123	CbGeAlD
Sorafenib—Nasopharyngitis—Telbivudine—hepatitis B	0.000509	0.00549	CcSEcCtD
Sorafenib—Jaundice—Adefovir Dipivoxil—hepatitis B	0.000507	0.00547	CcSEcCtD
Sorafenib—MAP3K7—blood—hepatitis B	0.000505	0.0121	CbGeAlD
Sorafenib—Hepatobiliary disease—Entecavir—hepatitis B	0.000505	0.00544	CcSEcCtD
Sorafenib—Gastritis—Telbivudine—hepatitis B	0.000503	0.00543	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Telbivudine—hepatitis B	0.000502	0.00541	CcSEcCtD
Sorafenib—Rhabdomyolysis—Lamivudine—hepatitis B	0.000499	0.00538	CcSEcCtD
Sorafenib—Hepatobiliary disease—Adefovir Dipivoxil—hepatitis B	0.000492	0.00531	CcSEcCtD
Sorafenib—BRAF—liver—hepatitis B	0.000491	0.0118	CbGeAlD
Sorafenib—MKNK2—blood—hepatitis B	0.000489	0.0117	CbGeAlD
Sorafenib—Bone disorder—Lamivudine—hepatitis B	0.000489	0.00527	CcSEcCtD
Sorafenib—CYP2C8—blood plasma—hepatitis B	0.000485	0.0116	CbGeAlD
Sorafenib—MKNK1—blood—hepatitis B	0.000483	0.0116	CbGeAlD
Sorafenib—RET—blood—hepatitis B	0.000477	0.0114	CbGeAlD
Sorafenib—Drug interaction—Lamivudine—hepatitis B	0.000476	0.00513	CcSEcCtD
Sorafenib—Abdominal discomfort—Telbivudine—hepatitis B	0.000471	0.00508	CcSEcCtD
Sorafenib—EPHX2—liver—hepatitis B	0.000469	0.0112	CbGeAlD
Sorafenib—FLT3—liver—hepatitis B	0.000466	0.0112	CbGeAlD
Sorafenib—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.000462	0.00498	CcSEcCtD
Sorafenib—Neutropenia—Telbivudine—hepatitis B	0.00046	0.00496	CcSEcCtD
Sorafenib—Connective tissue disorder—Adefovir Dipivoxil—hepatitis B	0.000459	0.00495	CcSEcCtD
Sorafenib—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.000458	0.00494	CcSEcCtD
Sorafenib—CYP1A2—blood plasma—hepatitis B	0.000454	0.0109	CbGeAlD
Sorafenib—RALBP1—blood—hepatitis B	0.000442	0.0106	CbGeAlD
Sorafenib—CYP3A5—blood plasma—hepatitis B	0.000438	0.0105	CbGeAlD
Sorafenib—CYP2B6—blood plasma—hepatitis B	0.000435	0.0104	CbGeAlD
Sorafenib—Immune system disorder—Entecavir—hepatitis B	0.000433	0.00467	CcSEcCtD
Sorafenib—CYP2C9—blood plasma—hepatitis B	0.000431	0.0103	CbGeAlD
Sorafenib—Renal failure—Telbivudine—hepatitis B	0.000431	0.00465	CcSEcCtD
Sorafenib—Neuropathy peripheral—Telbivudine—hepatitis B	0.00043	0.00463	CcSEcCtD
Sorafenib—UGT1A9—liver—hepatitis B	0.000429	0.0103	CbGeAlD
Sorafenib—Alopecia—Entecavir—hepatitis B	0.000423	0.00457	CcSEcCtD
Sorafenib—FLT4—liver—hepatitis B	0.000423	0.0101	CbGeAlD
Sorafenib—FLT1—blood—hepatitis B	0.00042	0.0101	CbGeAlD
Sorafenib—Mental disorder—Entecavir—hepatitis B	0.00042	0.00453	CcSEcCtD
Sorafenib—RAF1—blood—hepatitis B	0.000418	0.01	CbGeAlD
Sorafenib—FGFR1—liver—hepatitis B	0.000417	0.00999	CbGeAlD
Sorafenib—Malnutrition—Entecavir—hepatitis B	0.000417	0.0045	CcSEcCtD
Sorafenib—EPHB6—blood—hepatitis B	0.000416	0.00995	CbGeAlD
Sorafenib—Neuropathy—Lamivudine—hepatitis B	0.000415	0.00447	CcSEcCtD
Sorafenib—Hepatobiliary disease—Telbivudine—hepatitis B	0.000415	0.00447	CcSEcCtD
Sorafenib—Malnutrition—Adefovir Dipivoxil—hepatitis B	0.000407	0.00439	CcSEcCtD
Sorafenib—Mouth ulceration—Lamivudine—hepatitis B	0.000399	0.00431	CcSEcCtD
Sorafenib—STK10—blood—hepatitis B	0.000398	0.00953	CbGeAlD
Sorafenib—Gynaecomastia—Lamivudine—hepatitis B	0.000395	0.00426	CcSEcCtD
Sorafenib—MAP3K7—liver—hepatitis B	0.000395	0.00946	CbGeAlD
Sorafenib—PDGFRA—blood—hepatitis B	0.000394	0.00944	CbGeAlD
Sorafenib—Connective tissue disorder—Telbivudine—hepatitis B	0.000387	0.00417	CcSEcCtD
Sorafenib—MKNK2—liver—hepatitis B	0.000383	0.00917	CbGeAlD
Sorafenib—MKNK1—liver—hepatitis B	0.000378	0.00905	CbGeAlD
Sorafenib—Anaemia—Adefovir Dipivoxil—hepatitis B	0.000376	0.00406	CcSEcCtD
Sorafenib—UGT1A1—blood—hepatitis B	0.000376	0.009	CbGeAlD
Sorafenib—Leukopenia—Entecavir—hepatitis B	0.000373	0.00403	CcSEcCtD
Sorafenib—CYP3A7—liver—hepatitis B	0.000357	0.00854	CbGeAlD
Sorafenib—MAP2K5—blood—hepatitis B	0.000355	0.00851	CbGeAlD
Sorafenib—KDR—blood—hepatitis B	0.000355	0.00851	CbGeAlD
Sorafenib—Cough—Adefovir Dipivoxil—hepatitis B	0.000355	0.00383	CcSEcCtD
Sorafenib—Mediastinal disorder—Telbivudine—hepatitis B	0.000355	0.00383	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.000353	0.0038	CcSEcCtD
Sorafenib—CSF1R—blood—hepatitis B	0.000347	0.00831	CbGeAlD
Sorafenib—Myalgia—Adefovir Dipivoxil—hepatitis B	0.000346	0.00374	CcSEcCtD
Sorafenib—RALBP1—liver—hepatitis B	0.000346	0.00828	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.000344	0.00371	CcSEcCtD
Sorafenib—Malnutrition—Telbivudine—hepatitis B	0.000343	0.00369	CcSEcCtD
Sorafenib—Anaphylactic shock—Entecavir—hepatitis B	0.00034	0.00367	CcSEcCtD
Sorafenib—Infection—Entecavir—hepatitis B	0.000338	0.00365	CcSEcCtD
Sorafenib—Dysgeusia—Telbivudine—hepatitis B	0.000335	0.00362	CcSEcCtD
Sorafenib—Nervous system disorder—Entecavir—hepatitis B	0.000334	0.0036	CcSEcCtD
Sorafenib—Skin disorder—Entecavir—hepatitis B	0.000331	0.00357	CcSEcCtD
Sorafenib—Muscle spasms—Telbivudine—hepatitis B	0.000329	0.00355	CcSEcCtD
Sorafenib—CYP3A4—blood plasma—hepatitis B	0.000329	0.00787	CbGeAlD
Sorafenib—FLT1—liver—hepatitis B	0.000329	0.00787	CbGeAlD
Sorafenib—RAF1—liver—hepatitis B	0.000327	0.00783	CbGeAlD
Sorafenib—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.000326	0.00351	CcSEcCtD
Sorafenib—Thrombocytopenia—Adefovir Dipivoxil—hepatitis B	0.000325	0.00351	CcSEcCtD
Sorafenib—CYP2D6—blood plasma—hepatitis B	0.000324	0.00775	CbGeAlD
Sorafenib—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.000323	0.00348	CcSEcCtD
Sorafenib—Anorexia—Adefovir Dipivoxil—hepatitis B	0.000317	0.00341	CcSEcCtD
Sorafenib—KIT—blood—hepatitis B	0.000315	0.00754	CbGeAlD
Sorafenib—STK10—liver—hepatitis B	0.000311	0.00745	CbGeAlD
Sorafenib—PDGFRA—liver—hepatitis B	0.000308	0.00738	CbGeAlD
Sorafenib—PDGFRB—blood—hepatitis B	0.000308	0.00737	CbGeAlD
Sorafenib—Mood swings—Lamivudine—hepatitis B	0.000304	0.00328	CcSEcCtD
Sorafenib—CYP3A7-CYP3A51P—liver—hepatitis B	0.000303	0.00726	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Adefovir Dipivoxil—hepatitis B	0.000303	0.00326	CcSEcCtD
Sorafenib—Dyspepsia—Entecavir—hepatitis B	0.0003	0.00323	CcSEcCtD
Sorafenib—Cough—Telbivudine—hepatitis B	0.000299	0.00322	CcSEcCtD
Sorafenib—Dehydration—Lamivudine—hepatitis B	0.000298	0.00322	CcSEcCtD
Sorafenib—UGT1A1—liver—hepatitis B	0.000294	0.00704	CbGeAlD
Sorafenib—Gastrointestinal disorder—Entecavir—hepatitis B	0.000294	0.00317	CcSEcCtD
Sorafenib—Fatigue—Entecavir—hepatitis B	0.000293	0.00316	CcSEcCtD
Sorafenib—Abdominal pain upper—Lamivudine—hepatitis B	0.000293	0.00316	CcSEcCtD
Sorafenib—Dyspepsia—Adefovir Dipivoxil—hepatitis B	0.000292	0.00315	CcSEcCtD
Sorafenib—Arthralgia—Telbivudine—hepatitis B	0.000292	0.00315	CcSEcCtD
Sorafenib—Myalgia—Telbivudine—hepatitis B	0.000292	0.00315	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.00029	0.00312	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Lamivudine—hepatitis B	0.000289	0.00311	CcSEcCtD
Sorafenib—Decreased appetite—Adefovir Dipivoxil—hepatitis B	0.000289	0.00311	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.000287	0.00309	CcSEcCtD
Sorafenib—Nasopharyngitis—Lamivudine—hepatitis B	0.000287	0.00309	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Lamivudine—hepatitis B	0.000283	0.00305	CcSEcCtD
Sorafenib—Gastrointestinal pain—Entecavir—hepatitis B	0.000278	0.003	CcSEcCtD
Sorafenib—KDR—liver—hepatitis B	0.000278	0.00666	CbGeAlD
Sorafenib—MAP2K5—liver—hepatitis B	0.000278	0.00666	CbGeAlD
Sorafenib—Dysphagia—Lamivudine—hepatitis B	0.000277	0.00299	CcSEcCtD
Sorafenib—Nervous system disorder—Telbivudine—hepatitis B	0.000274	0.00296	CcSEcCtD
Sorafenib—Thrombocytopenia—Telbivudine—hepatitis B	0.000274	0.00295	CcSEcCtD
Sorafenib—Pancreatitis—Lamivudine—hepatitis B	0.000272	0.00293	CcSEcCtD
Sorafenib—Skin disorder—Telbivudine—hepatitis B	0.000272	0.00293	CcSEcCtD
Sorafenib—Gastrointestinal pain—Adefovir Dipivoxil—hepatitis B	0.000272	0.00293	CcSEcCtD
Sorafenib—CSF1R—liver—hepatitis B	0.000271	0.0065	CbGeAlD
Sorafenib—Abdominal pain—Entecavir—hepatitis B	0.000269	0.0029	CcSEcCtD
Sorafenib—Body temperature increased—Entecavir—hepatitis B	0.000269	0.0029	CcSEcCtD
Sorafenib—Abdominal discomfort—Lamivudine—hepatitis B	0.000266	0.00286	CcSEcCtD
Sorafenib—Body temperature increased—Adefovir Dipivoxil—hepatitis B	0.000262	0.00283	CcSEcCtD
Sorafenib—Abdominal pain—Adefovir Dipivoxil—hepatitis B	0.000262	0.00283	CcSEcCtD
Sorafenib—Neutropenia—Lamivudine—hepatitis B	0.000259	0.00279	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Telbivudine—hepatitis B	0.000255	0.00275	CcSEcCtD
Sorafenib—KIT—liver—hepatitis B	0.000246	0.0059	CbGeAlD
Sorafenib—Dyspepsia—Telbivudine—hepatitis B	0.000246	0.00265	CcSEcCtD
Sorafenib—ABCC4—blood—hepatitis B	0.000245	0.00587	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Lamivudine—hepatitis B	0.000245	0.00264	CcSEcCtD
Sorafenib—Asthenia—Entecavir—hepatitis B	0.000244	0.00263	CcSEcCtD
Sorafenib—HTR2B—blood—hepatitis B	0.000244	0.00584	CbGeAlD
Sorafenib—Renal failure—Lamivudine—hepatitis B	0.000243	0.00262	CcSEcCtD
Sorafenib—Neuropathy peripheral—Lamivudine—hepatitis B	0.000242	0.00261	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Telbivudine—hepatitis B	0.000241	0.0026	CcSEcCtD
Sorafenib—Fatigue—Telbivudine—hepatitis B	0.000241	0.0026	CcSEcCtD
Sorafenib—Stomatitis—Lamivudine—hepatitis B	0.000241	0.0026	CcSEcCtD
Sorafenib—Jaundice—Lamivudine—hepatitis B	0.000241	0.0026	CcSEcCtD
Sorafenib—PDGFRB—liver—hepatitis B	0.000241	0.00576	CbGeAlD
Sorafenib—Pain—Telbivudine—hepatitis B	0.000239	0.00258	CcSEcCtD
Sorafenib—Asthenia—Adefovir Dipivoxil—hepatitis B	0.000238	0.00257	CcSEcCtD
Sorafenib—ABCC2—blood—hepatitis B	0.000237	0.00568	CbGeAlD
Sorafenib—Pruritus—Adefovir Dipivoxil—hepatitis B	0.000235	0.00253	CcSEcCtD
Sorafenib—Hepatobiliary disease—Lamivudine—hepatitis B	0.000234	0.00252	CcSEcCtD
Sorafenib—Epistaxis—Lamivudine—hepatitis B	0.000233	0.00251	CcSEcCtD
Sorafenib—Diarrhoea—Entecavir—hepatitis B	0.000233	0.00251	CcSEcCtD
Sorafenib—ABCB1—blood plasma—hepatitis B	0.000233	0.00557	CbGeAlD
Sorafenib—Vismodegib—ALB—hepatitis B	0.00023	1	CrCbGaD
Sorafenib—Gastrointestinal pain—Telbivudine—hepatitis B	0.000229	0.00247	CcSEcCtD
Sorafenib—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.000227	0.00245	CcSEcCtD
Sorafenib—Dizziness—Entecavir—hepatitis B	0.000225	0.00243	CcSEcCtD
Sorafenib—Abdominal pain—Telbivudine—hepatitis B	0.000221	0.00238	CcSEcCtD
Sorafenib—Body temperature increased—Telbivudine—hepatitis B	0.000221	0.00238	CcSEcCtD
Sorafenib—Connective tissue disorder—Lamivudine—hepatitis B	0.000218	0.00235	CcSEcCtD
Sorafenib—Vomiting—Entecavir—hepatitis B	0.000216	0.00233	CcSEcCtD
Sorafenib—Rash—Entecavir—hepatitis B	0.000215	0.00231	CcSEcCtD
Sorafenib—Dermatitis—Entecavir—hepatitis B	0.000214	0.00231	CcSEcCtD
Sorafenib—Headache—Entecavir—hepatitis B	0.000213	0.0023	CcSEcCtD
Sorafenib—Vomiting—Adefovir Dipivoxil—hepatitis B	0.000211	0.00228	CcSEcCtD
Sorafenib—Erythema multiforme—Lamivudine—hepatitis B	0.00021	0.00226	CcSEcCtD
Sorafenib—Rash—Adefovir Dipivoxil—hepatitis B	0.000209	0.00226	CcSEcCtD
Sorafenib—Dermatitis—Adefovir Dipivoxil—hepatitis B	0.000209	0.00226	CcSEcCtD
Sorafenib—Headache—Adefovir Dipivoxil—hepatitis B	0.000208	0.00224	CcSEcCtD
Sorafenib—CYP2C19—blood—hepatitis B	0.000204	0.00488	CbGeAlD
Sorafenib—Nausea—Entecavir—hepatitis B	0.000202	0.00218	CcSEcCtD
Sorafenib—Asthenia—Telbivudine—hepatitis B	0.000201	0.00216	CcSEcCtD
Sorafenib—Immune system disorder—Lamivudine—hepatitis B	0.0002	0.00216	CcSEcCtD
Sorafenib—Mediastinal disorder—Lamivudine—hepatitis B	0.0002	0.00216	CcSEcCtD
Sorafenib—Pruritus—Telbivudine—hepatitis B	0.000198	0.00213	CcSEcCtD
Sorafenib—Nausea—Adefovir Dipivoxil—hepatitis B	0.000197	0.00213	CcSEcCtD
Sorafenib—Alopecia—Lamivudine—hepatitis B	0.000196	0.00211	CcSEcCtD
Sorafenib—Erythema—Lamivudine—hepatitis B	0.000193	0.00208	CcSEcCtD
Sorafenib—Malnutrition—Lamivudine—hepatitis B	0.000193	0.00208	CcSEcCtD
Sorafenib—ABCC4—liver—hepatitis B	0.000192	0.00459	CbGeAlD
Sorafenib—Diarrhoea—Telbivudine—hepatitis B	0.000191	0.00206	CcSEcCtD
Sorafenib—Dysgeusia—Lamivudine—hepatitis B	0.000189	0.00204	CcSEcCtD
Sorafenib—Muscle spasms—Lamivudine—hepatitis B	0.000186	0.002	CcSEcCtD
Sorafenib—ABCC2—liver—hepatitis B	0.000185	0.00444	CbGeAlD
Sorafenib—Dizziness—Telbivudine—hepatitis B	0.000185	0.00199	CcSEcCtD
Sorafenib—Anaemia—Lamivudine—hepatitis B	0.000178	0.00192	CcSEcCtD
Sorafenib—CYP2C8—blood—hepatitis B	0.000178	0.00426	CbGeAlD
Sorafenib—Vomiting—Telbivudine—hepatitis B	0.000178	0.00192	CcSEcCtD
Sorafenib—Angioedema—Lamivudine—hepatitis B	0.000176	0.0019	CcSEcCtD
Sorafenib—Rash—Telbivudine—hepatitis B	0.000176	0.0019	CcSEcCtD
Sorafenib—Dermatitis—Telbivudine—hepatitis B	0.000176	0.0019	CcSEcCtD
Sorafenib—Headache—Telbivudine—hepatitis B	0.000175	0.00189	CcSEcCtD
Sorafenib—Syncope—Lamivudine—hepatitis B	0.000173	0.00187	CcSEcCtD
Sorafenib—ABCG2—blood—hepatitis B	0.000173	0.00414	CbGeAlD
Sorafenib—Leukopenia—Lamivudine—hepatitis B	0.000173	0.00186	CcSEcCtD
Sorafenib—Loss of consciousness—Lamivudine—hepatitis B	0.00017	0.00183	CcSEcCtD
Sorafenib—Cough—Lamivudine—hepatitis B	0.000168	0.00182	CcSEcCtD
Sorafenib—CYP1A2—blood—hepatitis B	0.000166	0.00399	CbGeAlD
Sorafenib—Nausea—Telbivudine—hepatitis B	0.000166	0.00179	CcSEcCtD
Sorafenib—Arthralgia—Lamivudine—hepatitis B	0.000164	0.00177	CcSEcCtD
Sorafenib—Myalgia—Lamivudine—hepatitis B	0.000164	0.00177	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.000163	0.00176	CcSEcCtD
Sorafenib—Dry mouth—Lamivudine—hepatitis B	0.000161	0.00173	CcSEcCtD
Sorafenib—CYP3A5—blood—hepatitis B	0.00016	0.00384	CbGeAlD
Sorafenib—CYP2B6—blood—hepatitis B	0.00016	0.00382	CbGeAlD
Sorafenib—CYP2C19—liver—hepatitis B	0.000159	0.00382	CbGeAlD
Sorafenib—CYP2C9—blood—hepatitis B	0.000158	0.00378	CbGeAlD
Sorafenib—Anaphylactic shock—Lamivudine—hepatitis B	0.000158	0.0017	CcSEcCtD
Sorafenib—Infection—Lamivudine—hepatitis B	0.000157	0.00169	CcSEcCtD
Sorafenib—Shock—Lamivudine—hepatitis B	0.000155	0.00167	CcSEcCtD
Sorafenib—Nervous system disorder—Lamivudine—hepatitis B	0.000155	0.00167	CcSEcCtD
Sorafenib—Thrombocytopenia—Lamivudine—hepatitis B	0.000154	0.00166	CcSEcCtD
Sorafenib—Skin disorder—Lamivudine—hepatitis B	0.000153	0.00165	CcSEcCtD
Sorafenib—Anorexia—Lamivudine—hepatitis B	0.00015	0.00162	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Lamivudine—hepatitis B	0.000144	0.00155	CcSEcCtD
Sorafenib—Dyspnoea—Lamivudine—hepatitis B	0.00014	0.00152	CcSEcCtD
Sorafenib—CYP2C8—liver—hepatitis B	0.000139	0.00333	CbGeAlD
Sorafenib—Dyspepsia—Lamivudine—hepatitis B	0.000139	0.0015	CcSEcCtD
Sorafenib—Decreased appetite—Lamivudine—hepatitis B	0.000137	0.00148	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Lamivudine—hepatitis B	0.000136	0.00147	CcSEcCtD
Sorafenib—Fatigue—Lamivudine—hepatitis B	0.000136	0.00147	CcSEcCtD
Sorafenib—ABCG2—liver—hepatitis B	0.000135	0.00324	CbGeAlD
Sorafenib—Constipation—Lamivudine—hepatitis B	0.000135	0.00145	CcSEcCtD
Sorafenib—Pain—Lamivudine—hepatitis B	0.000135	0.00145	CcSEcCtD
Sorafenib—CYP1A2—liver—hepatitis B	0.00013	0.00312	CbGeAlD
Sorafenib—Gastrointestinal pain—Lamivudine—hepatitis B	0.000129	0.00139	CcSEcCtD
Sorafenib—CYP3A5—liver—hepatitis B	0.000126	0.00301	CbGeAlD
Sorafenib—Urticaria—Lamivudine—hepatitis B	0.000125	0.00135	CcSEcCtD
Sorafenib—CYP2B6—liver—hepatitis B	0.000125	0.00299	CbGeAlD
Sorafenib—Abdominal pain—Lamivudine—hepatitis B	0.000125	0.00134	CcSEcCtD
Sorafenib—Body temperature increased—Lamivudine—hepatitis B	0.000125	0.00134	CcSEcCtD
Sorafenib—CYP2C9—liver—hepatitis B	0.000124	0.00296	CbGeAlD
Sorafenib—CYP3A4—blood—hepatitis B	0.00012	0.00288	CbGeAlD
Sorafenib—CYP2D6—blood—hepatitis B	0.000119	0.00284	CbGeAlD
Sorafenib—Hypersensitivity—Lamivudine—hepatitis B	0.000116	0.00125	CcSEcCtD
Sorafenib—Asthenia—Lamivudine—hepatitis B	0.000113	0.00122	CcSEcCtD
Sorafenib—Pruritus—Lamivudine—hepatitis B	0.000111	0.0012	CcSEcCtD
Sorafenib—Diarrhoea—Lamivudine—hepatitis B	0.000108	0.00116	CcSEcCtD
Sorafenib—Dizziness—Lamivudine—hepatitis B	0.000104	0.00112	CcSEcCtD
Sorafenib—Vomiting—Lamivudine—hepatitis B	0.0001	0.00108	CcSEcCtD
Sorafenib—Rash—Lamivudine—hepatitis B	9.93e-05	0.00107	CcSEcCtD
Sorafenib—Dermatitis—Lamivudine—hepatitis B	9.92e-05	0.00107	CcSEcCtD
Sorafenib—Headache—Lamivudine—hepatitis B	9.87e-05	0.00106	CcSEcCtD
Sorafenib—CYP3A4—liver—hepatitis B	9.42e-05	0.00226	CbGeAlD
Sorafenib—Nausea—Lamivudine—hepatitis B	9.36e-05	0.00101	CcSEcCtD
Sorafenib—CYP2D6—liver—hepatitis B	9.27e-05	0.00222	CbGeAlD
Sorafenib—ABCB1—blood—hepatitis B	8.53e-05	0.00204	CbGeAlD
Sorafenib—ABCB1—liver—hepatitis B	6.67e-05	0.0016	CbGeAlD
Sorafenib—KIT—Immune System—PTEN—hepatitis B	3.89e-06	5.55e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—PTEN—hepatitis B	3.89e-06	5.55e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—NFKB1—hepatitis B	3.87e-06	5.52e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—NFKB1—hepatitis B	3.87e-06	5.52e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—hepatitis B	3.85e-06	5.49e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CD4—hepatitis B	3.83e-06	5.46e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CTNNB1—hepatitis B	3.78e-06	5.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CTNNB1—hepatitis B	3.77e-06	5.39e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—F2—hepatitis B	3.76e-06	5.37e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCR5—hepatitis B	3.76e-06	5.36e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—F2—hepatitis B	3.75e-06	5.36e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CDKN1A—hepatitis B	3.7e-06	5.28e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—hepatitis B	3.69e-06	5.27e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—PTEN—hepatitis B	3.69e-06	5.26e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CDKN1A—hepatitis B	3.69e-06	5.26e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—CTNNB1—hepatitis B	3.68e-06	5.25e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—PTEN—hepatitis B	3.68e-06	5.25e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL2—hepatitis B	3.68e-06	5.25e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NFKB1—hepatitis B	3.67e-06	5.24e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NFKB1—hepatitis B	3.66e-06	5.22e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—hepatitis B	3.64e-06	5.19e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKR1B1—hepatitis B	3.61e-06	5.15e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GGT1—hepatitis B	3.6e-06	5.14e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—GOT1—hepatitis B	3.6e-06	5.14e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—CDKN1A—hepatitis B	3.6e-06	5.13e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—PTEN—hepatitis B	3.59e-06	5.12e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—IL6—hepatitis B	3.59e-06	5.12e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—hepatitis B	3.56e-06	5.07e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CD4—hepatitis B	3.53e-06	5.04e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL2—hepatitis B	3.53e-06	5.04e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IFNG—hepatitis B	3.53e-06	5.04e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GOT2—hepatitis B	3.53e-06	5.04e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL2—hepatitis B	3.52e-06	5.03e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GOT1—hepatitis B	3.52e-06	5.02e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—GGT1—hepatitis B	3.52e-06	5.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCR5—hepatitis B	3.51e-06	5.01e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CTNNB1—hepatitis B	3.49e-06	4.99e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CTNNB1—hepatitis B	3.49e-06	4.97e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CYP2A6—hepatitis B	3.48e-06	4.97e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GGT2—hepatitis B	3.46e-06	4.93e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL2—hepatitis B	3.44e-06	4.92e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL2—hepatitis B	3.44e-06	4.9e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CDKN1A—hepatitis B	3.41e-06	4.87e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CD4—hepatitis B	3.41e-06	4.87e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CTNNB1—hepatitis B	3.41e-06	4.87e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PTEN—hepatitis B	3.41e-06	4.86e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CDKN1A—hepatitis B	3.4e-06	4.86e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CTNNB1—hepatitis B	3.4e-06	4.85e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—hepatitis B	3.4e-06	4.85e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP2A6—hepatitis B	3.4e-06	4.85e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PTEN—hepatitis B	3.4e-06	4.85e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—F2—hepatitis B	3.38e-06	4.83e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—hepatitis B	3.38e-06	4.82e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CDKN1A—hepatitis B	3.33e-06	4.76e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PTEN—hepatitis B	3.33e-06	4.75e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CTNNB1—hepatitis B	3.33e-06	4.74e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—hepatitis B	3.32e-06	4.74e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CDKN1A—hepatitis B	3.32e-06	4.74e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PTEN—hepatitis B	3.31e-06	4.73e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NFKB1—hepatitis B	3.31e-06	4.72e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NFKB1—hepatitis B	3.3e-06	4.71e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—TGFB1—hepatitis B	3.27e-06	4.66e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—IL2—hepatitis B	3.27e-06	4.66e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CDKN1A—hepatitis B	3.25e-06	4.64e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hepatitis B	3.25e-06	4.64e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PTEN—hepatitis B	3.24e-06	4.62e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—F2—hepatitis B	3.23e-06	4.6e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NFKB1—hepatitis B	3.23e-06	4.6e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP2A6—hepatitis B	3.2e-06	4.57e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP2A6—hepatitis B	3.18e-06	4.53e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—hepatitis B	3.17e-06	4.52e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—hepatitis B	3.15e-06	4.5e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GOT2—hepatitis B	3.15e-06	4.5e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2—hepatitis B	3.14e-06	4.48e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CTNNB1—hepatitis B	3.14e-06	4.48e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ALB—hepatitis B	3.08e-06	4.39e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ALB—hepatitis B	3.08e-06	4.39e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GOT2—hepatitis B	3.07e-06	4.39e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CDKN1A—hepatitis B	3.07e-06	4.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PTEN—hepatitis B	3.06e-06	4.37e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GOT1—hepatitis B	3.05e-06	4.35e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—GGT1—hepatitis B	3.05e-06	4.35e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—hepatitis B	3.04e-06	4.34e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCR5—hepatitis B	3.03e-06	4.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CTNNB1—hepatitis B	3.03e-06	4.33e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ALB—hepatitis B	3.01e-06	4.3e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—F2—hepatitis B	3.01e-06	4.3e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—hepatitis B	2.97e-06	4.25e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2—hepatitis B	2.97e-06	4.23e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2—hepatitis B	2.96e-06	4.23e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hepatitis B	2.96e-06	4.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CDKN1A—hepatitis B	2.96e-06	4.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PTEN—hepatitis B	2.95e-06	4.22e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NFKB1—hepatitis B	2.94e-06	4.2e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2—hepatitis B	2.93e-06	4.19e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GOT2—hepatitis B	2.9e-06	4.13e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GOT2—hepatitis B	2.87e-06	4.1e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CTNNB1—hepatitis B	2.86e-06	4.08e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CTNNB1—hepatitis B	2.83e-06	4.04e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—hepatitis B	2.82e-06	4.03e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—hepatitis B	2.82e-06	4.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CTNNB1—hepatitis B	2.8e-06	3.99e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CDKN1A—hepatitis B	2.79e-06	3.99e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PTEN—hepatitis B	2.79e-06	3.98e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	2.78e-06	3.96e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NFKB1—hepatitis B	2.77e-06	3.96e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CDKN1A—hepatitis B	2.77e-06	3.95e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PTEN—hepatitis B	2.76e-06	3.94e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—hepatitis B	2.76e-06	3.93e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NFKB1—hepatitis B	2.75e-06	3.92e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CDKN1A—hepatitis B	2.73e-06	3.9e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTEN—hepatitis B	2.73e-06	3.89e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GGT1—hepatitis B	2.72e-06	3.88e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GOT1—hepatitis B	2.72e-06	3.88e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP2A6—hepatitis B	2.71e-06	3.87e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—hepatitis B	2.69e-06	3.84e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—hepatitis B	2.69e-06	3.83e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2—hepatitis B	2.67e-06	3.81e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2—hepatitis B	2.67e-06	3.81e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GGT1—hepatitis B	2.65e-06	3.79e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GOT1—hepatitis B	2.65e-06	3.79e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—hepatitis B	2.61e-06	3.73e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—F2—hepatitis B	2.6e-06	3.71e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—hepatitis B	2.59e-06	3.69e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CTNNB1—hepatitis B	2.58e-06	3.68e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CTNNB1—hepatitis B	2.58e-06	3.68e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—hepatitis B	2.54e-06	3.62e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—hepatitis B	2.53e-06	3.62e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hepatitis B	2.53e-06	3.61e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—hepatitis B	2.53e-06	3.61e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CDKN1A—hepatitis B	2.52e-06	3.59e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CDKN1A—hepatitis B	2.52e-06	3.59e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PTEN—hepatitis B	2.51e-06	3.59e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PTEN—hepatitis B	2.51e-06	3.59e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GOT1—hepatitis B	2.5e-06	3.57e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GGT1—hepatitis B	2.5e-06	3.57e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NFKB1—hepatitis B	2.5e-06	3.57e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NFKB1—hepatitis B	2.5e-06	3.57e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GGT1—hepatitis B	2.48e-06	3.54e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GOT1—hepatitis B	2.48e-06	3.54e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	2.48e-06	3.54e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—hepatitis B	2.46e-06	3.51e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GOT2—hepatitis B	2.45e-06	3.5e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CTNNB1—hepatitis B	2.45e-06	3.49e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CTNNB1—hepatitis B	2.44e-06	3.48e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—hepatitis B	2.43e-06	3.46e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—hepatitis B	2.43e-06	3.46e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CDKN1A—hepatitis B	2.39e-06	3.41e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PTEN—hepatitis B	2.38e-06	3.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CDKN1A—hepatitis B	2.38e-06	3.4e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PTEN—hepatitis B	2.38e-06	3.39e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NFKB1—hepatitis B	2.37e-06	3.39e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NFKB1—hepatitis B	2.37e-06	3.38e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTEN—hepatitis B	2.35e-06	3.35e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTEN—hepatitis B	2.35e-06	3.35e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—hepatitis B	2.31e-06	3.3e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—hepatitis B	2.3e-06	3.29e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—hepatitis B	2.3e-06	3.28e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—hepatitis B	2.29e-06	3.27e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—hepatitis B	2.28e-06	3.25e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—hepatitis B	2.27e-06	3.24e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—hepatitis B	2.26e-06	3.23e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	2.26e-06	3.22e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—hepatitis B	2.24e-06	3.2e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—hepatitis B	2.21e-06	3.16e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CTNNB1—hepatitis B	2.2e-06	3.14e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—hepatitis B	2.17e-06	3.1e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—hepatitis B	2.16e-06	3.08e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CDKN1A—hepatitis B	2.15e-06	3.06e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTEN—hepatitis B	2.14e-06	3.06e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NFKB1—hepatitis B	2.13e-06	3.04e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—hepatitis B	2.13e-06	3.04e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—hepatitis B	2.12e-06	3.03e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GGT1—hepatitis B	2.12e-06	3.02e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GOT1—hepatitis B	2.12e-06	3.02e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CTNNB1—hepatitis B	2.1e-06	2.99e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2A6—hepatitis B	2.09e-06	2.99e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—hepatitis B	2.08e-06	2.97e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—hepatitis B	2.08e-06	2.97e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—hepatitis B	2.08e-06	2.96e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—hepatitis B	2.07e-06	2.95e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1A—hepatitis B	2.05e-06	2.92e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTEN—hepatitis B	2.04e-06	2.92e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NFKB1—hepatitis B	2.03e-06	2.9e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—hepatitis B	2.03e-06	2.9e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—hepatitis B	2.02e-06	2.89e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—hepatitis B	2.02e-06	2.88e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTEN—hepatitis B	1.99e-06	2.84e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—hepatitis B	1.98e-06	2.82e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTEN—hepatitis B	1.97e-06	2.82e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—hepatitis B	1.97e-06	2.81e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CTNNB1—hepatitis B	1.96e-06	2.8e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	1.93e-06	2.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1A—hepatitis B	1.91e-06	2.73e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—hepatitis B	1.91e-06	2.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—hepatitis B	1.91e-06	2.73e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—hepatitis B	1.91e-06	2.73e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—hepatitis B	1.9e-06	2.71e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NFKB1—hepatitis B	1.9e-06	2.71e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT2—hepatitis B	1.89e-06	2.7e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—hepatitis B	1.88e-06	2.69e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—hepatitis B	1.87e-06	2.67e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—hepatitis B	1.85e-06	2.63e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—hepatitis B	1.78e-06	2.54e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—hepatitis B	1.75e-06	2.5e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—hepatitis B	1.74e-06	2.49e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—hepatitis B	1.74e-06	2.48e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—hepatitis B	1.72e-06	2.46e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—hepatitis B	1.71e-06	2.45e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—hepatitis B	1.71e-06	2.45e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—hepatitis B	1.7e-06	2.43e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—hepatitis B	1.69e-06	2.42e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CTNNB1—hepatitis B	1.69e-06	2.41e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1A—hepatitis B	1.65e-06	2.36e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—hepatitis B	1.65e-06	2.35e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NFKB1—hepatitis B	1.64e-06	2.34e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT1—hepatitis B	1.64e-06	2.33e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GGT1—hepatitis B	1.64e-06	2.33e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—hepatitis B	1.63e-06	2.32e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—hepatitis B	1.62e-06	2.32e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—hepatitis B	1.62e-06	2.31e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—hepatitis B	1.58e-06	2.26e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—hepatitis B	1.57e-06	2.24e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—hepatitis B	1.57e-06	2.24e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—hepatitis B	1.49e-06	2.13e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—hepatitis B	1.49e-06	2.12e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—hepatitis B	1.46e-06	2.09e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—hepatitis B	1.46e-06	2.08e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—hepatitis B	1.45e-06	2.06e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—hepatitis B	1.43e-06	2.04e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—hepatitis B	1.41e-06	2.01e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—hepatitis B	1.39e-06	1.99e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—hepatitis B	1.37e-06	1.95e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—hepatitis B	1.34e-06	1.91e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—hepatitis B	1.33e-06	1.9e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—hepatitis B	1.32e-06	1.88e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—hepatitis B	1.3e-06	1.86e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—hepatitis B	1.28e-06	1.82e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—hepatitis B	1.24e-06	1.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—hepatitis B	1.19e-06	1.7e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—hepatitis B	1.13e-06	1.61e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—hepatitis B	1.13e-06	1.61e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—hepatitis B	1.1e-06	1.57e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—hepatitis B	1.08e-06	1.54e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—hepatitis B	1.03e-06	1.47e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—hepatitis B	1.02e-06	1.45e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—hepatitis B	1.01e-06	1.44e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—hepatitis B	8.7e-07	1.24e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—hepatitis B	8.6e-07	1.23e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—hepatitis B	6.64e-07	9.47e-06	CbGpPWpGaD
